Neuronetics, Inc. (NASDAQ:STIM - Free Report) - William Blair cut their Q2 2025 EPS estimates for Neuronetics in a research note issued to investors on Tuesday, May 6th. William Blair analyst M. Andrew now forecasts that the company will post earnings per share of ($0.09) for the quarter, down from their prior forecast of ($0.08). The consensus estimate for Neuronetics' current full-year earnings is ($1.13) per share. William Blair also issued estimates for Neuronetics' Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.00 EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at ($0.10) EPS.
Neuronetics (NASDAQ:STIM - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%. The firm had revenue of $31.98 million during the quarter, compared to analysts' expectations of $29.07 million.
Separately, Canaccord Genuity Group raised their price target on shares of Neuronetics from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th.
Get Our Latest Report on Neuronetics
Neuronetics Stock Down 6.5%
Shares of NASDAQ STIM traded down $0.29 during midday trading on Friday, hitting $4.14. The company's stock had a trading volume of 1,085,070 shares, compared to its average volume of 728,008. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The firm has a market capitalization of $272.47 million, a price-to-earnings ratio of -3.37 and a beta of 1.92. The business's fifty day simple moving average is $4.23 and its two-hundred day simple moving average is $2.87. Neuronetics has a 1 year low of $0.52 and a 1 year high of $5.92.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Balyasny Asset Management L.P. grew its holdings in shares of Neuronetics by 29.5% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company's stock worth $2,386,000 after purchasing an additional 337,539 shares during the last quarter. CenterBook Partners LP acquired a new position in Neuronetics during the first quarter worth approximately $1,200,000. Geode Capital Management LLC boosted its holdings in shares of Neuronetics by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 314,076 shares of the company's stock valued at $506,000 after acquiring an additional 8,466 shares during the period. Nkcfo LLC acquired a new position in shares of Neuronetics in the 1st quarter valued at $460,000. Finally, Assenagon Asset Management S.A. purchased a new stake in Neuronetics in the 1st quarter valued at $359,000. 53.59% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Neuronetics
In related news, CFO Stephen Furlong sold 10,845 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $41,536.35. Following the transaction, the chief financial officer now owns 471,727 shares of the company's stock, valued at $1,806,714.41. This represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP William Andrew Macan sold 12,175 shares of Neuronetics stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $46,630.25. Following the sale, the executive vice president now directly owns 388,647 shares of the company's stock, valued at $1,488,518.01. This trade represents a 3.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,571 shares of company stock valued at $169,351. Insiders own 8.70% of the company's stock.
Neuronetics Company Profile
(
Get Free Report)
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
See Also
Before you consider Neuronetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neuronetics wasn't on the list.
While Neuronetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
